CARsgen Announced 2022 Annual Results and Business Updates
- Written by PR Newswire
![]() |
SHANGHAI, March 22, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced its 2022 Annual Results.
Business Highlights
- Zevor-cel (CT053) NDA was accepted by the NMPA (Oct 2022) with priority...
Read more: CARsgen Announced 2022 Annual Results and Business Updates